Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety
Authors:
- 11 August 2011
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 118 (6) , 1495-1503
Abstract
Adoptive T-cell therapy for malignancies using redirected T cells genetically engineered by tumor antigen-specific T-cell receptor (TCR) gene transfer is associated with mispairing between introduced and endogenous TCR chains with unknown specificity. Therefore, deterioration of antitumor reactivity and serious autoimmune reactivity are major concerns. To address this problem, we have recently established a novel retroviral vector system encoding siRNAs for endogenous TCR genes (siTCR vector). In this study, to test the clinical application of siTCR gene therapy for human leukemia, we examined in detail the efficacy and safety of WT1-siTCR–transduced T cells. Compared with conventional WT1-TCR (WT1-coTCR) gene-transduced T cells, these cells showed significant enhancement of antileukemia reactivity resulting from stronger expression of the introduced WT1-specific TCR with inhibition of endogenous TCRs. Notably, WT1-siTCR gene-transduced T cells were remarkably expandable after repetitive stimulation with WT1 peptide in vitro, without any deterioration of antigen specificity. WT1-siTCR gene–transduced T cells from leukemia patients successfully lysed autologous leukemia cells, but not normal hematopoietic progenitor cells. In a mouse xenograft model, adoptively transferred WT1-siTCR gene-transduced T cells exerted distinct antileukemia efficacy but did not inhibit human hematopoiesis. Our results suggest that gene-immunotherapy for leukemia using this WT1-siTCR system holds considerable promise.Keywords
This publication has 41 references indexed in Scilit:
- Mixed T cell receptor dimers harbor potentially harmful neoreactivityProceedings of the National Academy of Sciences, 2010
- Immunotherapy prospects for acute myeloid leukaemiaClinical and Experimental Immunology, 2010
- Allo-HLA reactivity of virus-specific memory T cells is commonBlood, 2010
- Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem CellsScience Translational Medicine, 2010
- Lack of specific γ-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulationBlood, 2009
- Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID miceHaematologica, 2009
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenBlood, 2009
- Adoptive cell therapy for the treatment of patients with metastatic melanomaCurrent Opinion in Immunology, 2009
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complexBlood, 2006